IPI-549

DB16296InvestigationalSmall molecule

IPI-549 is under investigation in clinical trial NCT03795610 (Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma).

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
Curator reviewed
Formula / weight: C₃₀H₂₄N₈O₂ · 528.576 g/mol (avg)
Also known as: Eganelisib · Pi3k-gamma inhibitor ipi-549
Code names: IPI-549

Resolves to

Compound

UNIIFOF5155FMZCAS1693758-51-8ChEMBLCHEMBL3984425

Structure

InChIKeyXUMALORDVCFWKV-IBGZPJMESA-NSMILESC[C@H](NC(=O)C1=C2N=CC=CN2N=C1N)C1=CC2=C(C(=O)N1C1=CC=CC=C1)C(=CC=C2)C#CC1=CN(C)N=C1

Targets

P48736PIK3CG

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with IPI-549, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account